We currently have agreements with four suppliers for COVID-19 vaccines. These are Pfizer/BioNTech, Janssen Pharmaceutica, Novavax and AstraZeneca.
Last updated: 5 October 2021
On this page:
New Zealand has secured COVID-19 vaccines through Advance Purchase Agreements with pharmaceutical suppliers. We have agreements with four suppliers.
We've also bought enough vaccines for those in Cook Islands, Niue, Tokelau, Sāmoa, Tonga, and Tuvalu.
The Government has signed an advance purchase agreement for 8.5 million additional doses from Pfizer. Enough to vaccinate 4.25 million people.
Our first COVID-19 vaccine agreement was for 1.5 million COVID-19 vaccines from Pfizer.
The decision to make Pfizer our primary vaccine provider includes:
- it's shown to be approximately 95% effective against symptomatic COVID-19, seven days after receiving two doses
- all people in New Zealand will have the chance to access the same vaccine.
New Zealand secured 2 million doses of the Janssen vaccine through an advance purchase agreement in 2020.
Janssen is a single dose, viral vector vaccine. It can be stored at normal fridge temperatures (2C to 8C) for up to 3 months and in deep freezers (-20C to -15C) for up to two years.
Medsafe has granted provisional approval of the Janssen vaccine, but provisional approval does not mean that we have committed to using the Janssen vaccine in New Zealand.
We’ve agreed with Novavax to purchase 10.72 million doses of a COVID-19 vaccine. This vaccine needs two doses. Enough for 5.36 million people.
Following Medsafe’s regulatory decision on the safety and effectiveness of the Novavax COVID-19 vaccine, and once delivery timeframes have been confirmed, we will consider the use of Novavax in New Zealand.
An Advance Purchase Agreement of 7.6 million doses was signed with AstraZeneca. This vaccine needs two doses, so this amount is enough to fully vaccinate 3.8 million people.
AstraZeneca is a viral vector vaccine and can be stored at normal fridge temperatures (2C to 8C) for up to 6 months.
Medsafe has granted provisional approval of the AstraZeneca COVID-19 vaccine for individuals age 18 years of age and older. However, provisional approval does not mean that we have committed to using the AstraZeneca vaccine in New Zealand.